J&J Seeks Approval For Doxil Plus Velcade In Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental claim for liposomal doxorubicin has a May 21 priority review date, J&J’s Ortho Biotech unit tells “The Pink Sheet” DAILY.